Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-05-29
2007-05-29
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S143100, C530S387300, C530S388220, C536S023530
Reexamination Certificate
active
10103686
ABSTRACT:
Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
REFERENCES:
patent: 4629783 (1986-12-01), Cosand
patent: 4714759 (1987-12-01), Whitaker, Jr.
patent: 4940782 (1990-07-01), Rup et al.
patent: 4975369 (1990-12-01), Beavers et al.
patent: 5348876 (1994-09-01), Michaelsen et al.
patent: 5428133 (1995-06-01), Chang
patent: 5543144 (1996-08-01), Chang et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5635600 (1997-06-01), Fanger et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5648267 (1997-07-01), Reff
patent: 5658570 (1997-08-01), Newman et al.
patent: 5681722 (1997-10-01), Newman et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5811524 (1998-09-01), Brams et al.
patent: 6001358 (1999-12-01), Black et al.
patent: 6011138 (2000-01-01), Reff et al.
patent: 6136310 (2000-10-01), Hanna et al.
patent: 6383487 (2002-05-01), Amlot
patent: 6521230 (2003-02-01), Amlot
patent: WO 87/07302 (1987-12-01), None
patent: WO 88/06891 (1988-09-01), None
patent: WO 89/00138 (1989-01-01), None
patent: WO 92/17207 (1992-10-01), None
patent: WO 93/02108 (1993-02-01), None
patent: WO 96/12741 (1996-05-01), None
patent: WO 9612742 (1996-05-01), None
Webster's II New Riverside University Dictionary, p. 933, 1984.
Van Noort et al, International Reivew of Cytology 178: 127-205, 1998.
Abaza et al, J of Protein Chemistry 11(5): 433-444, 1992.
Plater-Zyberk et al, Nat Med 1(8): 781-785, Aug. 1995.
Wakai et al, Hybridoma 12(1): 25-43, 1993.
Swandorg et al, Clin Immunol Immunopathol 77(1):4-13, Oct. 1995.
Paul WE (ed),Fundamental Immunology, 2ndedition, Raven Press, New York, 1989, pp. 705, 870.
Muino JC et al., “The importance of specific IgG and IgE autoantibodies to retinal S antigen, total serum IgE, and sCD23 levels in autoimmune and infectious uveitis,”J Clin Immunol, 1999, 19: 215-222.
Rosenwasser LJ et al., “Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase 1, single-dose, dose-escalating clinical trial,”J Allergy Clin Immunol, 2003, 112: 563-570.
Soh H et al., “IgE and its related phenomena in bullous pemphigoid,”Br J Dermatol, 1993, 128: 371-377.
Yabuuchi S et al., “Anti-CD23 monoclonal antibody inhibits germline Cepsilon transcription in B cells,”Int Immunopharmacol, 2002, 2: 453-461.
Yoshikawa T et al., “Soluble Fc epsilon RII/CD23 in patients with autoimmune diseases and Epstein-Barr virus-related disorders: analysis by ELISA for soluble Fc epsilon RII/CD23,”Immunomethods, 1994, 4: 65-71.
Ngo et al., “Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox,” 1994,The Protein Folding Problem and Tertiary Structure Prediction, Birkhauser Boston, pp. 490-495.
Boulet et al. , “Inhibitory Effects of an Anti-Ige Antibody E25 on Allergen-induced Early Asthmatic Response,”Am J Respir Crit Care Med, (1997) 155:1835-44.
Casale et al., “Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis,”J Allergy Clin Immunol, (1997), 100:110-120.
Coyle et al., “Central Role of Immunoglobulin (Ig) E in the Induction of Lung Eosinophil Infiltration and T Helper 2 Cell Cytokine Production: Inhibition by a Non-anaphylactogenic Anti-IgE Antibody,”J Exp Med, (1996), 183:1303-1310.
Fahy et al., “The Effect of an Anti-IgE Monoclonal Antibody on the Early-and Late-Phase Responses to Allergen Inhalation in Asthmatic Subjects,”Am J Respir Crit Care Med, (1997), 155:1828-34.
Ohashi et al., “Immunotherapy Affects the Seasonal Increase in Specific IgE and Interleukin-4 in Serum of Patients with Seasonal Allergic Rhinitis,”Scan J Immunol, (1997), 46(1):67-77.
Ohashi et al., “Serum levels of specific IgE, soluble interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in seasonal allergic rhinitis,”Annals of Allergy, Asthma, and Immunol, (1997), 79:213-220.
Ohashi et al., “Ten-Year Follow-up Study of Allergen-Specific Immunoglobulin E and Immunoglobulin G4, Soluble Interleukin-2 Receptor, Interleukin-4, Soluble Intercellular Adhesion Molecule-1 and Soluble Vascular Cell Adhesion Molecule-1 in Serum of Patients on Immunotherapy for Perennial Allergic Rhinitis,”Scand J Immunol, (1998), 47:167-178.
Peebles et al., “Ragweed-specific antibodies in bronchoalveolar lavage fluids and serum before and after segmental lung challenge: IgE and IgA associated with eosinophil degranulation,”J Allergy Clin Immunol, (1998), 101:265-273.
Pullertis et al., “An intranasal glucocorticoid inhibits the increase of specific IgE initiated during birch pollen season,”J Allergy Clin Immunol, (1997), 100:601-605.
Reff et al., “Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20,”Blood, (1994), 83:435-445.
Ward E.S. and Ghetie V., “The effector functions of immunoglobulins: implications for therapy,” (1995),Therapeutic Immunology, 2:77-94.
Flores-Romo et al., “Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23”, Science, 261: 1038-1046 (1993).
Pene et al., “IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2”, Proc. Natl. Acad. Sci., USA, 85: 6880-6884 (1988).
Luo et al., “Cross-linking of CD23 antigen by its natural ligand (IgE) or by anti-CD23 antibody prevents B lymphocyte proliferation and differentiation”, J. Immunol., 146(7):2122-9 (1991).
Groves et al., “Production of an ovine monoclonal antibody to testosterone by an interspecies fusion”, Hybridoma, vol. 6(1):71 (1987).
Robbins, “Diseases of Immunity,” Pathologic Basis of Disease, pp. 197-199 (1994).
Seaver, “Monoclonal Antibodies in Industry: More Difficult than Oringally Thought,” Genetic Engineering, 14(14): 10 and 21 (1994).
Haak-Frendscho et al., “Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo”, Immunology, 82:306 (1994).
Delespesse et al., “Human IgE-binding factors”, Immunology Today, 10:159, (1989).
Durum and Oppenheim, “Proinflammatory Cytokines and Immunity,” Fundamental Immunology, 3rd Edition, ed. by Paul et al., Chapter 21, p. 801-835, Raven Press Ltd. (1993).
Vercelli et al., “Induction of human IgE synthesis requires interluekin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens”, J. Exp. Med., 169:1295 (Apr. 1989).
Bonnefoy et al., “Production and characterization of a monoclonal antibody specific for the human lymphocyte low affinity receptor for IgE: CD23 is a low affinity receptor for IgE,” J. Immunol., 138(9):2970-8.
Presta et al., “Humanization of an antibody directed against IgE”, J. Immunology, 151(5):2623 (Sep. 1993).
Strike et al., “Production of human-human hybridomas secreting antibody to sheep erythrocytes after in vitro immunization”, J. Immunol., 132(4): 1798 (Apr. 1984).
Cruse et al., Illustrated Dictionary of Immunology, CRC Press, p. 69 (1995).
Capon et al., “Designing CD4 immunoadhesin for AIDS therapy”, Nature, 337:525 (Feb. 1989).
Rector et al., “Detection and characterization of monoclonal antibodies specific to IgE receptors on human lymphocytes by flow cytometry”, Immunol., 55: 481-488 (1985).
Suemura et al., “Monoclonal anti-Fc epsilon receptor antibodies with different specificities and studies on the expression of
Kloetzer William S.
Nakamura Takehiko
Reff Mitchell E.
Biogen Idec MA Inc.
Chan Christina
Huynh Phuong
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3729534